MAPK9

Across TCGA pan-cancer cohorts, MAPK9 mass-spec protein is linked to patient survival in 6 of 34 cancer types, making it a survival-associated MAPK9 data layer compared with 24 for mass-spec protein and 7 for mutation status.

The strongest signal is observed in uterine corpus endometrial carcinoma (UCEC), where higher MAPK9 mass-spec protein is associated with worse overall survival. In most high-consensus cancer types, elevated MAPK9 expression acts as an unfavorable survival marker, although some lineages such as CCRCC and LUAD show a favorable association.

UCEC, CCRCC, and LUAD are the cancer types where MAPK9 mass-spec protein most reproducibly stratifies survival.

mass-spec protein survival associations by lineage

Ranked by sampling consensus. AUC1 and AUC2 indicate survival in the high- and low-expression groups, respectively; the lower AUC marks the poorer-surviving group. p-values are from the log-rank test.

Lineage	Measure	Split	Stage	AUC1 high	AUC2 low	p	Sampling consensus
UCEC	OS	Quartile	II,III,IV	0.520	1.000	.026	8	view →
CCRCC	DFS	Median	II,III,IV	0.935	0.802	.019	8	view →
LUAD	DFS	Median	All	0.832	0.655	.019	7	view →
LSCC	OS	Tertile	II,III,IV	0.615	0.947	.006	6	view →
HNSC	DFS	Median	IV	0.932	0.672	.007	6	view →
GBM	OS	Median	All	0.603	0.920	.003	2	view →

Pink = unfavorable, green = favorable. Showing the 6 strongest of 6 lineages.

MAPK9–UCEC (OS)

Open the UCEC breakdown →